Clark, NJ, United States of America

Yining Ji Chen

This inventor holds 1 USPTO granted patent. Top assignee: Merck Sharp & Dohme LLC. Active years: 2026.


% Patents Active = 100.0

Average Co-Inventor Count = 19.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Yining Ji Chen: Innovator in Fluorinated Nucleotides

Introduction

Yining Ji Chen is a notable inventor based in Clark, NJ (US). He has made significant contributions to the field of biochemistry, particularly in the synthesis of fluorinated nucleotides. His work is essential for advancements in various applications, including pharmaceuticals and molecular biology.

Latest Patents

Yining Ji Chen holds a patent for the "Synthesis of Fluorinated Nucleotides." This innovation is crucial for developing new therapeutic agents and enhancing the efficacy of existing drugs. His patent portfolio reflects his commitment to advancing scientific knowledge and practical applications in his field. He has 1 patent to his name.

Career Highlights

Yining Ji Chen is currently employed at Merck Sharp & Dohme LLC, a leading global healthcare company. His role at Merck allows him to collaborate with other talented professionals and contribute to groundbreaking research. His expertise in nucleotide synthesis positions him as a valuable asset to the company and the scientific community.

Collaborations

Yining Ji Chen has worked alongside notable colleagues, including Jeffrey C. Moore and Heather Claire Johnson. Their collaborative efforts have fostered an environment of innovation and creativity, leading to significant advancements in their respective fields.

Conclusion

Yining Ji Chen's contributions to the synthesis of fluorinated nucleotides exemplify his dedication to innovation in biochemistry. His work at Merck Sharp & Dohme LLC and his collaborations with esteemed colleagues highlight his impact on the scientific community.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…